Cantor Fitzgerald Comments on SLNO FY2026 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Soleno Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn $1.22 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share.

Several other research analysts have also recently issued reports on the company. Guggenheim increased their price objective on Soleno Therapeutics from $81.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. UBS Group set a $105.00 price objective on Soleno Therapeutics in a research report on Thursday, March 27th. Laidlaw increased their price objective on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research report on Thursday, March 27th. Finally, Piper Sandler increased their price objective on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $106.78.

Soleno Therapeutics Stock Down 0.8%

Shares of NASDAQ SLNO traded down $0.65 during mid-day trading on Tuesday, hitting $79.15. 806,442 shares of the company were exchanged, compared to its average volume of 764,482. The stock has a 50 day simple moving average of $72.80 and a 200-day simple moving average of $57.46. Soleno Therapeutics has a 1-year low of $36.93 and a 1-year high of $80.99. The firm has a market cap of $3.99 billion, a price-to-earnings ratio of -23.84 and a beta of -2.69.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.19.

Institutional Trading of Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. AlphaQuest LLC boosted its stake in Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock worth $32,000 after buying an additional 658 shares during the last quarter. US Bancorp DE acquired a new stake in Soleno Therapeutics in the 4th quarter worth about $34,000. Quarry LP acquired a new stake in Soleno Therapeutics in the 1st quarter worth about $121,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in Soleno Therapeutics in the 4th quarter worth about $81,000. Finally, Avanza Fonder AB boosted its stake in Soleno Therapeutics by 14.8% in the 1st quarter. Avanza Fonder AB now owns 1,951 shares of the company's stock worth $144,000 after buying an additional 251 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

Insider Activity

In related news, CEO Bhatnagar Anish sold 699,095 shares of Soleno Therapeutics stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. This trade represents a 54.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patricia C. Hirano sold 128,653 shares of Soleno Therapeutics stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $68.32, for a total value of $8,789,572.96. Following the sale, the insider now owns 55,789 shares of the company's stock, valued at approximately $3,811,504.48. This represents a 69.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 942,672 shares of company stock worth $64,058,781 over the last 90 days. 12.30% of the stock is currently owned by corporate insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.